Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques with Novel Molecularly Selective Agents

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Treatment for chronic, locoregional pain ranks among the most prevalent unmet medical needs. The failure of systemic analgesic drugs, such as opioids, is often due to their off-target toxicity, development of tolerance, and abuse potential. Interventional pain procedures provide target specificity but lack pharmacologically selective agents with long-term efficacy. Gene therapy vectors are a new tool for the development of molecularly selective pain therapies, which have already been proved to provide durable analgesia in preclinical models. Taken together, advances in image-guided delivery and gene therapy may lead to a new class of dual selective analgesic treatments integrating the molecular selectivity of analgesic genes with the anatomic selectivity of interventional delivery techniques.

Original languageEnglish (US)
Pages (from-to)522-533
Number of pages12
JournalMayo Clinic Proceedings
Volume91
Issue number4
DOIs
StatePublished - Apr 1 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques with Novel Molecularly Selective Agents'. Together they form a unique fingerprint.

  • Cite this